Evidence map›Paper›PMID 37414557›Full record

ArticleBMJ quality & safety2023

Initial opioid prescription characteristics and risk of opioid misuse, poisoning and dependence: retrospective cohort study.

Aníbal García-Sempere, Isabel Hurtado, Celia Robles, Fran Llopis-Cardona, Francisco Sánchez-Saez, Clara Rodriguez-Bernal, Salvador Peiró-Moreno, Gabriel Sanfélix-Gimeno

Open access · hybridAbstract read
In one paragraph

Article in BMJ quality & safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Aníbal García-SempereHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.ORCID 0000-0002-4313-3976
Isabel HurtadoHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain hurtado_isa@gva.es.
Celia RoblesHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.
Fran Llopis-CardonaHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.
Francisco Sánchez-SaezHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.ORCID 0000-0002-3011-9884
Clara Rodriguez-BernalHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.
Salvador Peiró-MorenoHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.
Gabriel Sanfélix-GimenoHealth Services Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo identify individual and initial prescription-related factors associated with an increased risk for opioid-related misuse, poisoning and dependence (MPD) in patients with non-cancer pain.

methodsCohort study linking several databases covering 5 million inhabitants of the region of Valencia, Spain, including all adults initiating prescription opioids in the period 2012-2018. To ascertain the association between the characteristics of the initial prescription choice and the risk of opioid MPD, we used shared frailty Cox regression models. We additionally considered death as a competing risk in sensitivity analyses.

results958 019 patients initiated opioid prescription from 2012 to 2018, of which 0.13% experienced MPD. Most patients were prescribed tramadol as initial opioid (76.7%) followed by codeine (16.3%), long-acting opioids (6.7%), short-acting opioids (0.2%) and ultrafast opioids (0.1%). Initiation with ultrafast (HR 7.2; 95% CI 4.1 to 12.6), short-acting (HR 4.8; 95% CI 2.3 to 10.2) and long-acting opioids (HR 1.5; 95% CI 1.2 to 1.9) were associated with a higher risk of MPD when compared with tramadol. Initial prescriptions covering 4-7 days (HR 1.3; 95% CI 1.0 to 1.8), 8-14 days (HR 1.4; 95% CI 1.0 to 1.9), 15-30 days (HR 1.7; 95% CI 1.2 to 2.3) and more than one a month (HR 1.8; 95% CI 1.3 to 2.5) were associated with more MPD risk than initial prescriptions for 1-3 days. Treatments with >120 daily morphine milligram equivalents (MME) increased MPD risk (vs <50 MME, HR 1.6; 95% CI 1.1 to 2.2). Main individual factors associated with increased risk of MPD risk were male sex (HR 2.4; 95% CI 2.1 to 2.7), younger age (when compared with patients aged 18-44 years, patients aged 45-64 years, HR 0.4; 95% CI 0.4 to 0.5; patients aged 65-74 years, HR 0.4; 95% CI 0.3 to 0.5 and patients aged 75 years old and over, HR 0.7; 95% CI 0.6 to 0.8), lack of economic resources (2.1; 95% CI 1.8 to 2.5) and registered misuse of alcohol (2.9; 95% CI 2.4 to 3.5). Sensitivity analyses yielded overall comparable results.

conclusionsOur study identifies riskier patterns of opioid prescription initiation for non-cancer indications, as well as patient subgroups with higher risk of misuse, poisoning and dependence.

Indexed as

Opioid-Related DisordersTramadolAdultAgedAnalgesics, OpioidCohort StudiesEndrinFemaleHumansMalePractice Patterns, Physicians'PrescriptionsRetrospective StudiesAnalgesics, OpioidEndrinMMETramadoladverse events, epidemiology and detectionhealth services researchmedication safetypainpharmacoepidemiology

Identifiers

PMID37414557
PMCPMC10804034
OpenAlexW4383337757

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.